{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T18:36:25Z","timestamp":1788287785094,"version":"build-2803163510"},"reference-count":54,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100010665","name":"Horizon 2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.xphs.2021.09.008","type":"journal-article","created":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T20:30:30Z","timestamp":1631305830000},"page":"164-174","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Lipophilic Salts and Lipid-Based Formulations for Bridging the Food Effect Gap of Venetoclax"],"prefix":"10.1016","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0565-9192","authenticated-orcid":false,"given":"Niklas J.","family":"Koehl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J.","family":"Henze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Holm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kuentz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1186-3149","authenticated-orcid":false,"given":"John J.","family":"Keating","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8692-425X","authenticated-orcid":false,"given":"Thomas","family":"De Vijlder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Marx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5433-8398","authenticated-orcid":false,"given":"Brendan T.","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9\u201310","key":"10.1016\/j.xphs.2021.09.008_bib0001","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.drudis.2011.11.007","article-title":"Bridging solubility between drug discovery and development","volume":"17","author":"Di","year":"2012","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.xphs.2021.09.008_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.addr.2016.05.016","article-title":"Understanding the challenge of beyond-rule-of-5 compounds","volume":"101","author":"Bergstrom","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"issue":"7","key":"10.1016\/j.xphs.2021.09.008_bib0003","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1021\/acs.jmedchem.7b00717","article-title":"Beyond the rule of 5: lessons learned from AbbVie's drugs and compound collection","volume":"61","author":"DeGoey","year":"2018","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.xphs.2021.09.008_bib0004","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1016\/j.ddtec.2012.03.002","article-title":"Lipid-based formulations for oral delivery of lipophilic drugs","volume":"9","author":"Kuentz","year":"2012","journal-title":"Drug Discov Today Technol"},{"issue":"4","key":"10.1016\/j.xphs.2021.09.008_bib0005","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/jphp.12957","article-title":"Food for thought: formulating away the food effect - a PEARRL review","volume":"71","author":"O\u2019Shea","year":"2019","journal-title":"J Pharm Pharmacol"},{"issue":"1","key":"10.1016\/j.xphs.2021.09.008_bib0006","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1023\/A:1018922517162","article-title":"Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine in a crossover comparison with the market formulation","volume":"11","author":"Mueller","year":"1994","journal-title":"Pharm Res"},{"issue":"5","key":"10.1016\/j.xphs.2021.09.008_bib0007","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.jaad.2013.05.036","article-title":"Comparative pharmacokinetic profiles of a novel isotretinoin formulation (isotretinoin-Lidose) and the innovator isotretinoin formulation: a randomized, 4-treatment, crossover study","volume":"69","author":"Webster","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.xphs.2021.09.008_bib0008","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nrd2197","article-title":"Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs","volume":"6","author":"Porter","year":"2007","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"10.1016\/j.xphs.2021.09.008_bib0009","doi-asserted-by":"crossref","DOI":"10.1007\/s11095-019-2590-y","article-title":"New insights into using lipid based suspensions for \"brick dust\u2019 molecules: case study of nilotinib","volume":"36","author":"Koehl","year":"2019","journal-title":"Pharm Res-Dordr"},{"issue":"9","key":"10.1016\/j.xphs.2021.09.008_bib0010","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1021\/acs.molpharmaceut.0c00305","article-title":"Exploring the impact of surfactant type and digestion: highly digestible surfactants improve oral bioavailability of nilotinib","volume":"17","author":"Koehl","year":"2020","journal-title":"Mol Pharm"},{"issue":"7","key":"10.1016\/j.xphs.2021.09.008_bib0011","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s11095-020-02841-9","article-title":"Chase dosing of lipid formulations to enhance oral bioavailability of nilotinib in rats","volume":"37","author":"Koehl","year":"2020","journal-title":"Pharm Res"},{"issue":"1","key":"10.1016\/j.xphs.2021.09.008_bib0012","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejpb.2007.01.017","article-title":"The effect of different lipid based formulations on the oral absorption of lipophilic drugs: the ability of in vitro lipolysis and consecutive ex vivo intestinal permeability data to predict in vivo bioavailability in rats","volume":"67","author":"Dahan","year":"2007","journal-title":"Eur J Pharm Biopharm"},{"issue":"9","key":"10.1016\/j.xphs.2021.09.008_bib0013","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1002\/jps.2600620918","article-title":"Biopharmaceutics of drugs administered in lipid-containing dosage forms. I. GI absorption of griseofulvin from an oil-in-water emulsion in the rat","volume":"62","author":"Carrigan","year":"1973","journal-title":"J Pharm Sci"},{"issue":"4","key":"10.1016\/j.xphs.2021.09.008_bib0014","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/jphp.12984","article-title":"Lipophilicity and hydrophobicity considerations in bio-enabling oral formulations approaches - a PEARRL review","volume":"71","author":"Ditzinger","year":"2019","journal-title":"J Pharm Pharmacol"},{"issue":"3","key":"10.1016\/j.xphs.2021.09.008_bib0015","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1080\/03639045.2020.1721526","article-title":"Supersaturated lipid-based drug delivery systems - exploring impact of lipid composition type and drug properties on supersaturability and physical stability","volume":"46","author":"Ilie","year":"2020","journal-title":"Drug Dev Ind Pharm"},{"issue":"1","key":"10.1016\/j.xphs.2021.09.008_bib0016","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1208\/s12248-012-9433-7","article-title":"Supersaturated self-nanoemulsifying drug delivery systems (Super-SNEDDS) enhance the bioavailability of the poorly water-soluble drug simvastatin in dogs","volume":"15","author":"Thomas","year":"2013","journal-title":"Aaps J"},{"issue":"1","key":"10.1016\/j.xphs.2021.09.008_bib0017","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jconrel.2012.02.027","article-title":"In vitro and in vivo performance of novel supersaturated self-nanoemulsifying drug delivery systems (super-SNEDDS)","volume":"160","author":"Thomas","year":"2012","journal-title":"J Control Release"},{"issue":"6","key":"10.1016\/j.xphs.2021.09.008_bib0018","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3390\/pharmaceutics12060564","article-title":"Supersaturated lipid-based formulations to enhance the oral bioavailability of Venetoclax","volume":"12","author":"Koehl","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.xphs.2021.09.008_bib0019","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ejpb.2017.04.021","article-title":"Lipophilic salts of poorly soluble compounds to enable high-dose lipidic SEDDS formulations in drug discovery","volume":"117","author":"Morgen","year":"2017","journal-title":"Eur J Pharm Biopharm"},{"issue":"6","key":"10.1016\/j.xphs.2021.09.008_bib0020","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1021\/mp500790t","article-title":"Transformation of poorly water-soluble drugs into lipophilic ionic liquids enhances oral drug exposure from lipid based formulations","volume":"12","author":"Sahbaz","year":"2015","journal-title":"Mol Pharm"},{"issue":"1","key":"10.1016\/j.xphs.2021.09.008_bib0021","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12010017","article-title":"Ionic liquid forms of the antimalarial lumefantrine in combination with LFCS type IIIB lipid-based formulations preferentially increase lipid solubility, in vitro solubilization behavior and in vivo exposure","volume":"12","author":"Tay","year":"2019","journal-title":"Pharmaceutics"},{"issue":"12","key":"10.1016\/j.xphs.2021.09.008_bib0022","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.1021\/acs.molpharmaceut.8b00858","article-title":"Enhancing the oral absorption of kinase inhibitors using lipophilic salts and lipid-based formulations","volume":"15","author":"Williams","year":"2018","journal-title":"Mol Pharm"},{"issue":"1","key":"10.1016\/j.xphs.2021.09.008_bib0023","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.xphs.2017.05.019","article-title":"Transformation of biopharmaceutical classification system class i and iii drugs into ionic liquids and lipophilic salts for enhanced developability using lipid formulations","volume":"107","author":"Williams","year":"2018","journal-title":"J Pharm Sci"},{"issue":"6","key":"10.1016\/j.xphs.2021.09.008_bib0024","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/cmdc.201100082","article-title":"Ionic liquids as active pharmaceutical ingredients","volume":"6","author":"Ferraz","year":"2011","journal-title":"ChemMedChem"},{"issue":"12","key":"10.1016\/j.xphs.2021.09.008_bib0025","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1246\/bcsj.80.2262","article-title":"Ionic liquids then and now: from solvents to materials to active pharmaceutical ingredients","volume":"80","author":"Hough","year":"2007","journal-title":"B Chem Soc Jpn"},{"key":"10.1016\/j.xphs.2021.09.008_bib0026","series-title":"Compositions and Preparation Methods of Low Melting Ionic Salts of Poorly-Water Soluble Drugs","author":"Porter","year":"2014"},{"key":"10.1016\/j.xphs.2021.09.008_bib0027","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.addr.2019.05.008","article-title":"Unlocking the full potential of lipid-based formulations using lipophilic salt\/ionic liquid forms","volume":"142","author":"Williams","year":"2019","journal-title":"Adv Drug Deliv Rev"},{"issue":"22","key":"10.1016\/j.xphs.2021.09.008_bib0028","doi-asserted-by":"crossref","first-page":"12788","DOI":"10.1039\/D0RA00386G","article-title":"API ionic liquids: probing the effect of counterion structure on physical form and lipid solubility","volume":"10","author":"Ford","year":"2020","journal-title":"Rsc Adv"},{"issue":"11","key":"10.1016\/j.xphs.2021.09.008_bib0029","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1021\/acs.molpharmaceut.7b00442","article-title":"Ionic liquid forms of weakly acidic drugs in oral lipid formulations: preparation, characterization, in vitro digestion, and in vivo absorption studies","volume":"14","author":"Sahbaz","year":"2017","journal-title":"Mol Pharm"},{"issue":"1","key":"10.1016\/j.xphs.2021.09.008_bib0030","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.xphs.2017.09.027","article-title":"Mechanistic physiologically based pharmacokinetic modeling of the dissolution and food effect of a biopharmaceutics classification system IV compound-the venetoclax story","volume":"107","author":"Emami Riedmaier","year":"2018","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2021.09.008_bib0031","unstructured":"FDA. Venclexta (Venetoclax) Clinical Pharmacology and Biopharmaceutics Review(s) Application Number: 208573Orig1s000. U.S. Department of Health and Human Services; 2015. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/208573Orig1s000ClinPharmR.pdf. Accessed October 4, 2021."},{"key":"10.1016\/j.xphs.2021.09.008_bib0032","unstructured":"EMEA. Assessment Report Venclyxto Procedure No. EMEA\/H\/C\/004106\/0000. Committee for Medicinal Products for Human Use (CHMP); 2016. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/venclyxto-epar-public-assessment-report_en.pdf. Accessed October 4, 2021."},{"issue":"6","key":"10.1016\/j.xphs.2021.09.008_bib0033","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1021\/acs.molpharmaceut.0c00645","article-title":"In silico, in vitro and in vivo evaluation of precipitation inhibitors in supersaturated lipid-based formulations of venetoclax","volume":"18","author":"Koehl","year":"2021","journal-title":"Mol Pharmaceut"},{"issue":"3","key":"10.1016\/j.xphs.2021.09.008_bib0034","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1208\/s12248-010-9203-3","article-title":"The use of biorelevant dissolution media to forecast the in vivo performance of a drug","volume":"12","author":"Klein","year":"2010","journal-title":"Aaps J"},{"issue":"2","key":"10.1016\/j.xphs.2021.09.008_bib0035","doi-asserted-by":"crossref","first-page":"16","DOI":"10.14227\/DT110204P16","article-title":"Dissolution media simulating fasted and fed states","volume":"11","author":"Marques","year":"2004","journal-title":"Dissol Technol"},{"issue":"10","key":"10.1016\/j.xphs.2021.09.008_bib0036","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.1021\/cg5007007","article-title":"Kinetic entrapment of a hidden curcumin cocrystal with phloroglucinol","volume":"14","author":"Chow","year":"2014","journal-title":"Cryst Growth Des"},{"key":"10.1016\/j.xphs.2021.09.008_bib0037","unstructured":"Guidance for Industry Food-Effect Bioavailability and Fed Bioequivalence Studies. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER); 2002. https:\/\/www.fda.gov\/media\/70945\/download. Accessed October 4, 2021."},{"key":"10.1016\/j.xphs.2021.09.008_bib0038","article-title":"Toward the establishment of a standardized pre-clinical porcine model to predict food effects - Case studies on fenofibrate and paracetamol","volume":"1","author":"Henze","year":"2019","journal-title":"Int J Pharm X"},{"key":"10.1016\/j.xphs.2021.09.008_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.105840","article-title":"Combining species specific in vitro & in silico models to predict in vivo food effect in a preclinical stage - case study of Venetoclax","volume":"162","author":"Henze","year":"2021","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.xphs.2021.09.008_bib0040","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.enconman.2014.02.045","article-title":"Stearic\u2013capric acid eutectic\/activated-attapulgiate composite as form-stable phase change material for thermal energy storage","volume":"81","author":"Song","year":"2014","journal-title":"Energy Convers Manag"},{"key":"10.1016\/j.xphs.2021.09.008_bib0041","unstructured":"FDA. Regulatory Calssification of Pharamceutical Co-Crystals Guidance for Industry. FDA-2011-D-0800. Revision 1 U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER); 2018. https:\/\/www.fda.gov\/media\/81824\/download. Accessed October 4, 2021."},{"issue":"10","key":"10.1016\/j.xphs.2021.09.008_bib0042","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.addr.2012.07.012","article-title":"Fatty acids as therapeutic auxiliaries for oral and parenteral formulations","volume":"65","author":"Hackett","year":"2013","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.xphs.2021.09.008_bib0043","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.addr.2019.01.009","article-title":"Bridging the gaps between academic research and industrial product developments of lipid-based formulations","volume":"142","author":"Holm","year":"2019","journal-title":"Adv Drug Deliv Rev"},{"issue":"1\u20132","key":"10.1016\/j.xphs.2021.09.008_bib0044","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ijpharm.2011.03.002","article-title":"In vitro lipolysis models as a tool for the characterization of oral lipid and surfactant based drug delivery systems","volume":"417","author":"Larsen","year":"2011","journal-title":"Int J Pharmaceut"},{"issue":"11","key":"10.1016\/j.xphs.2021.09.008_bib0045","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1002\/jps.20886","article-title":"Evaluation of drug precipitation of solubility-enhancing liquid formulations using milligram quantities of a new molecular entity (NME)","volume":"96","author":"Dai","year":"2007","journal-title":"J Pharm Sci"},{"issue":"10","key":"10.1016\/j.xphs.2021.09.008_bib0046","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1002\/jps.21659","article-title":"Design of lipid-based formulations for oral administration of poorly water-soluble drugs: precipitation of drug after dispersion of formulations in aqueous solution","volume":"98","author":"Mohsin","year":"2009","journal-title":"J Pharm Sci-Us"},{"issue":"11","key":"10.1016\/j.xphs.2021.09.008_bib0047","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1021\/mp300331z","article-title":"Toward the establishment of standardized in vitro tests for lipid-based formulations. 2. The effect of bile salt concentration and drug loading on the performance of type I, II, IIIA, IIIB, and IV formulations during in vitro digestion","volume":"9","author":"Williams","year":"2012","journal-title":"Mol Pharm"},{"issue":"12","key":"10.1016\/j.xphs.2021.09.008_bib0048","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1007\/s11095-013-1038-z","article-title":"Toward the establishment of standardized in vitro tests for lipid-based formulations, Part 3: understanding supersaturation versus precipitation potential during the in vitro digestion of type I, II, IIIA, IIIB and IV lipid-based formulations","volume":"30","author":"Williams","year":"2013","journal-title":"Pharm Res"},{"issue":"3","key":"10.1016\/j.xphs.2021.09.008_bib0049","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1021\/mp900063t","article-title":"Dry hybrid lipid-silica microcapsules engineered from submicron lipid droplets and nanoparticles as a novel delivery system for poorly soluble drugs","volume":"6","author":"Simovic","year":"2009","journal-title":"Mol Pharm"},{"issue":"1","key":"10.1016\/j.xphs.2021.09.008_bib0050","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jconrel.2008.10.014","article-title":"Silica-lipid hybrid (SLH) microcapsules: a novel oral delivery system for poorly soluble drugs","volume":"134","author":"Tan","year":"2009","journal-title":"J Control Release"},{"key":"10.1016\/j.xphs.2021.09.008_bib0051","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.addr.2016.04.007","article-title":"50years of oral lipid-based formulations: provenance, progress and future perspectives","volume":"101","author":"Feeney","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"10.1016\/j.xphs.2021.09.008_bib0052","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1124\/dmd.113.055053","article-title":"The role of lymphatic transport on the systemic bioavailability of the Bcl-2 protein family inhibitors navitoclax (ABT-263) and ABT-199","volume":"42","author":"Choo","year":"2014","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.xphs.2021.09.008_bib0053","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S0928-0987(02)00051-9","article-title":"Lipid-based formulations for intestinal lymphatic delivery","volume":"15","author":"O'Driscoll","year":"2002","journal-title":"Eur J Pharm Sci"},{"issue":"3","key":"10.1016\/j.xphs.2021.09.008_bib0054","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1211\/jpp.62.03.0006","article-title":"Bioavailability of lycopene in the rat: the role of intestinal lymphatic transport","volume":"62","author":"Faisal","year":"2010","journal-title":"J Pharm Pharmacol"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354921004755?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354921004755?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:36:46Z","timestamp":1758361006000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354921004755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0022354921004755"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2021.09.008","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipophilic Salts and Lipid-Based Formulations for Bridging the Food Effect Gap of Venetoclax","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2021.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}